Midatech Pharma PLC American Depositary Shs - ADR
$0.13
$-10.39
(-98.75%)
As on 26-May-2023 09:30EDT
Market cap
$2 Mln
Revenue (TTM)
$-- Mln
P/E Ratio
--
P/B Ratio
0.7
Div. Yield
0 %
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
$-- Mln
-
ROE
-1 %
-
ROCE
-- %
-
Industry P/E
--
-
EV/EBITDA
0
-
Debt to Equity
0.2
-
Book Value
$--
-
EPS
$--
-
Face value
--
-
Shares outstanding
6,933,870
10 Years Aggregate
CFO
£-90.65 Mln
EBITDA
£-111.65 Mln
Net Profit
£-117.26 Mln
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Midatech Pharma PLC American Depositary Shs - ADR
| -100.0 | -99.3 | -99.9 | -100.0 | -96.1 | -92.6 | -- |
|
BSE Sensex*
| -11.2 | -4.2 | -10.2 | -8.7 | 7.0 | 8.4 | 11.3 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2022
|
2021
|
2020
|
2019
|
2018
|
2017
|
2016
|
|---|---|---|---|---|---|---|---|
|
Midatech Pharma PLC American Depositary Shs - ADR
| -81.2 | -43.9 | -45.7 | -55.5 | -81.3 | -69.2 | -43.1 |
|
S&P Small-Cap 600
| -17.4 | 25.3 | 9.6 | 20.9 | -9.7 | 11.7 | 24.7 |
|
BSE Sensex
| 4.4 | 22.0 | 15.8 | 14.4 | 5.9 | 27.9 | 1.9 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Shareholding Pattern
View DetailsAbout Midatech Pharma PLC American Depositary Shs - ADR
Biodexa Pharmaceuticals Plc, a drug delivery technology company, focuses on the research and development of medicines in the United Kingdom, rest of Europe, and internationally. The company is developing MTX110, a direct delivery treatment for... diffuse intrinsic pontine glioma, medulloblastomas, and glioblastoma multiforme; MTX114, an immuno-suppressant for topical application in psoriasis; MTD211, a long-acting formulation of brexpiprazole for the treatment of schizophrenia and adjunctive treatment of major depressive disorder; and MTD219, a long-acting formulation of tacrolimus used to lower the risk of organ transplant rejection. It also offers drug delivery platforms, such as Q-Sphera, a polymer microsphere microtechnology used for sustained release drug delivery; MidaSolve, an oligosaccharide nanotechnology used to solubilize drugs so that they can be administered in liquid form directly and locally into tumors; and MidaCore, a gold nanoparticle used for targeting sites of disease by using chemotherapeutic agents or immunotherapeutic agents. The company was formerly known as Midatech Pharma plc and changed its name to Biodexa Pharmaceuticals Plc in March 2023. Biodexa Pharmaceuticals Plc was founded in 2000 and is headquartered in Cardiff, the United Kingdom. Read more
-
CEO, CFO, Company Sec. & Director
Mr. Stephen A. Stamp
-
CEO, CFO, Company Sec. & Director
Mr. Stephen A. Stamp
-
Headquarters
Cardiff
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for Midatech Pharma PLC American Depositary Shs - ADR
What is the current share price of Midatech Pharma PLC American Depositary Shs - ADR Today?
The share price of Midatech Pharma PLC American Depositary Shs - ADR is $0.13 (NASDAQ) as of 26-May-2023 09:30 EDT. Midatech Pharma PLC American Depositary Shs - ADR has given a return of -96.13% in the last 3 years.
What is the current PB & PE ratio of Midatech Pharma PLC American Depositary Shs - ADR?
Since, TTM earnings of Midatech Pharma PLC American Depositary Shs - ADR is negative, P/E ratio is not available.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2022
|
--
|
--
|
|
2021
|
--
|
--
|
|
2020
|
--
|
--
|
|
2019
|
--
|
--
|
|
2018
|
--
|
--
|
What is the 52 Week High and Low of Midatech Pharma PLC American Depositary Shs - ADR?
The 52-week high and low of Midatech Pharma PLC American Depositary Shs - ADR are Rs -- and Rs -- as of 19-May-2026.
What is the market cap of Midatech Pharma PLC American Depositary Shs - ADR?
Midatech Pharma PLC American Depositary Shs - ADR has a market capitalisation of $ 2 Mln as on 26-May-2023. As per SEBI classification, it is a Small Cap company.
Should I invest in Midatech Pharma PLC American Depositary Shs - ADR?
Before investing in Midatech Pharma PLC American Depositary Shs - ADR, assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.